Gynecologic Cancer MSK 17-452 Light

This is a non-randomized, open-label study to assess olaparib tablets as a treatment for subjects with different homologous recombination deficiency (HRD) tumor status and with platinum-sensitive, relapsed, high-grade serous or high-grade endometrioid ovarian cancer. Subjects should have received at least 1 prior line of platinum-based chemotherapy.

Eligibility Criteria: Provision of written signed informed consent prior to any study specific procedures. Female subjects with histologically diagnosed relapsed high-grade serous or high-grade endometrioid ovarian cancer. At least 1 lesion (measurable by RECIST v1.1) that can be accurately assessed at baseline by computed tomography (CT)/magnetic resonance imaging (MRI) and is suitable for repeated assessment. Subjects must have received at least 1 prior platinum-based line of chemotherapy for ovarian cancer. Note: There is no limit on the number of lines of chemotherapy.

This study is for patients age 18 to 130 Years.

Available at: Hartford Hospital, the Hospital of Central Connecticut